Astellas, Poseida Announce Investment To Support Poseida's Commitment To Cancer Cell Therapy

RTTNews | Před 646 dny
Astellas, Poseida Announce Investment To Support Poseida's Commitment To Cancer Cell Therapy

(RTTNews) - Pharmaceutical companies Astellas Pharma Inc. (ALPMY.PK) and Poseida Therapeutics, Inc. (PSTX) announced Monday a strategic investment to support the advancement of Poseida's commitment to redefining cancer cell therapy.

Under the terms of the transaction agreements, Astellas will invest a total of $50 million, including $25 million to acquire 8.3 million shares of common stock of Poseida or approximately 8.8% of the outstanding common stock of Poseida, at $3.00 per share in a private placement.

It will also make a one-time $25 million payment for a right of exclusive negotiation and first refusal to license one of Poseida's clinical stage programs: P-MUC1C-ALLO1, an allogeneic CAR-T cell therapy in development for multiple solid tumor indications.

In addition, Poseida has granted Astellas a board observer seat, which includes the ability to attend Poseida's scientific advisory board meetings, and certain notice rights related to any potential change of control of Poseida.

read more
Astellas Pharma Gets Positive CHMP Opinion For XTANDI In Early Prostate Cancer Treatment Setting

Astellas Pharma Gets Positive CHMP Opinion For XTANDI In Early Prostate Cancer Treatment Setting

Astellas Pharma Inc. announced Friday the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of XTANDI (enzalutamide) as monotherapy or in combination with androgen deprivation therapy for the treatment of adult men with high risk biochemical recurrent (BCR) non-metastatic hormone sensitive prostate cancer (nmHSPC) who are unsuitable for salvage radiotherapy.
RTTNews | Před 418 dny
European Markets Close With Mild Losses

European Markets Close With Mild Losses

The major European stock markets finished moderately to the downside in cautious trade on Wednesday as benign U.S. inflation data prompted traders to pare back Fed rate cut bets for this year.
RTTNews | Před 10 minutami
Swiss Franc Weakens Against Majors

Swiss Franc Weakens Against Majors

The Swiss franc fell against its major counterparts in the New York session on Wednesday. The franc edged down to 1.1182 against the pound and 0.8436 against the greenback, from an early high of 1.1117 and a 5-day high of 0.8324, respectively.
RTTNews | Před 31 minutami
E.ON Confirms Outlook After Higher Q1 Adj. Earnings

E.ON Confirms Outlook After Higher Q1 Adj. Earnings

German utility E.ON SE reported Wednesday a significant increase in its first-quarter adjusted earnings and Group EBITDA with growth in all three core segments. Further, the firm affirmed its guidance for 2025 and its outlook through 2028. On the XETRA in Germany, E.ON shares were gaining around 1.36 percent.
RTTNews | Před 6 h 56 min
Yen Rises Against Majors

Yen Rises Against Majors

The Japanese yen strengthened against other major currencies in the European session on Wednesday.
RTTNews | Před 9 h 20 min
FTSE 100 Flat As Stocks Move In Tight Range

FTSE 100 Flat As Stocks Move In Tight Range

U.K. stocks are mostly subdued in lackluster trade on Wednesday as investors react to a mixed batch of earnings announcements, and await more economic data from the U.S., and clarity about Trump administration's stance on tariffs with regard to European countries.
RTTNews | Před 9 h 55 min